Correspondence re: A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters)

J. M. Gallo; U. Hafeli; A. S. Lubbe

Correspondence re: A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters)

J. M. Gallo
, U. Hafeli
, A. S. Lubbe

Pharmaceutical Sciences

Fox Chase Cancer Center

Research output: Contribution to journal › Letter › peer-review

24 Scopus citations

Original language	English
Pages (from-to)	3063-3065
Number of pages	3
Journal	Cancer Research
Volume	57
Issue number	14
State	Published - 1997

Fingerprint

Dive into the research topics of 'Correspondence re: A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters)'. Together they form a unique fingerprint.

Cite this

Gallo, J. M., Hafeli, U., & Lubbe, A. S. (1997). Correspondence re: A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters). Cancer Research, 57(14), 3063-3065.

Gallo, J. M. ; Hafeli, U. ; Lubbe, A. S. / Correspondence re : A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters). In: Cancer Research. 1997 ; Vol. 57, No. 14. pp. 3063-3065.

@article{d381d84b6ca14027a26d60b3dcc8b049,

title = "Correspondence re: A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters)",

author = "Gallo, \{J. M.\} and U. Hafeli and Lubbe, \{A. S.\}",

year = "1997",

language = "English",

volume = "57",

pages = "3063--3065",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "14",

}

Gallo, JM, Hafeli, U & Lubbe, AS 1997, 'Correspondence re: A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters)', Cancer Research, vol. 57, no. 14, pp. 3063-3065.

Correspondence re: A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters). / Gallo, J. M.; Hafeli, U.; Lubbe, A. S.
In: Cancer Research, Vol. 57, No. 14, 1997, p. 3063-3065.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Correspondence re

T2 - A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters)

AU - Gallo, J. M.

AU - Hafeli, U.

AU - Lubbe, A. S.

PY - 1997

Y1 - 1997

UR - https://www.scopus.com/pages/publications/0031570959

M3 - Letter

C2 - 9230223

AN - SCOPUS:0031570959

SN - 0008-5472

VL - 57

SP - 3063

EP - 3065

JO - Cancer Research

JF - Cancer Research

IS - 14

ER -

Gallo JM, Hafeli U, Lubbe AS. Correspondence re: A. S. Lubbe et al., Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer res., 56: 4686-4693, 1996 (multiple letters). Cancer Research. 1997;57(14):3063-3065.

Other files and links

Fingerprint

Cite this